322 related articles for article (PubMed ID: 29120971)
1. Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.
van den Elsen SHJ; Oostenbrink LM; Heysell SK; Hira D; Touw DJ; Akkerman OW; Bolhuis MS; Alffenaar JC
Ther Drug Monit; 2018 Feb; 40(1):17-37. PubMed ID: 29120971
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
3. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
6. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid.
Ray J; Gardiner I; Marriott D
Intern Med J; 2003; 33(5-6):229-34. PubMed ID: 12752892
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
van den Elsen SHJ; Akkerman OW; Jongedijk EM; Wessels M; Ghimire S; van der Werf TS; Touw DJ; Bolhuis MS; Alffenaar JC
Eur Respir J; 2020 May; 55(5):. PubMed ID: 31980497
[No Abstract] [Full Text] [Related]
9. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
[TBL] [Abstract][Full Text] [Related]
10. Does AIDS impair the absorption of antituberculosis agents?
Taylor B; Smith PJ
Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma.
Fage D; Brilleman R; Deprez G; Payen MC; Cotton F
J Pharm Biomed Anal; 2022 Jun; 215():114776. PubMed ID: 35462286
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care.
Koegelenberg CF; Nortje A; Lalla U; Enslin A; Irusen EM; Rosenkranz B; Seifart HI; Bolliger CT
S Afr Med J; 2013 Apr; 103(6):394-8. PubMed ID: 23725959
[TBL] [Abstract][Full Text] [Related]
13. Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers.
Teeninga N; Guan Z; Freijer J; Ruiter AF; Ackermans MT; Kist-van Holthe JE; van Gelder T; Nauta J
Ther Drug Monit; 2013 Aug; 35(4):485-92. PubMed ID: 23783167
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.
Liu H; Delgado MR
Clin Pharmacokinet; 1999 Jun; 36(6):453-70. PubMed ID: 10427469
[TBL] [Abstract][Full Text] [Related]
15. Salivary and urinary excretion and plasma-saliva concentration ratios of isoniazid in the presence of Co-administered ciprofloxacin.
Ofoefule SI; Obodo CE; Orisakwe OE; Afonne JO; Ilondu NA; Agbasi PU; Anusiem CA; Maduka SO; Ilo CE
Am J Ther; 2002; 9(1):15-8. PubMed ID: 11782814
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
Babalık A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildiz L; Çarpaner E
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1442-7. PubMed ID: 24125448
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring in saliva. An update.
Drobitch RK; Svensson CK
Clin Pharmacokinet; 1992 Nov; 23(5):365-79. PubMed ID: 1478004
[TBL] [Abstract][Full Text] [Related]
19. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
Ghimire S; Maharjan B; Jongedijk EM; Kosterink JGW; Ghimire GR; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JC
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
